<DOC>
	<DOCNO>NCT01357252</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy safety vildagliptin 50mg qd add-on therapy sulfonylurea patient type 2 diabetes inadequately control prior sulfonylurea monotherapy compare placebo . This study aim support regulatory approval China vildagliptin combination therapy sulfonylureas treatment type 2 diabetes .</brief_summary>
	<brief_title>Vildagliptin add-on Glimepiride Versus Placebo Added Glimepiride Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>1 . Confirmed diagnosis T2DM standard criterion 2 . Patients receive stable dose SU least 12 week prior Visit 1 3 . HbA1c ≥7.5 % ≤ 11.0 % Visit 1 Visit 3 ( Week 1 ) 4 . Age : ≥18 ≤ 80 year Visit 1 . 5 . BMI ≥ 20 ≤ 40 kg/m^2 visit 1 . 1 . FPG ≥ 270mg/dl ( 15.0 mmol/L ) Visit 1 Visit 3 ( Week 1 ) 2 . Severe repetitive hypoglycemia , define section 3.1 , runin period ( Visit 2 Visit 4 ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Diabetes mellitus</keyword>
	<keyword>vildagliptin</keyword>
</DOC>